search
Back to results

Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali (LAKANA)

Primary Purpose

Mortality

Status
Recruiting
Phase
Phase 3
Locations
Mali
Study Type
Interventional
Intervention
Placebo
Azithromycin
Sponsored by
Tampere University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mortality focused on measuring Mass Drug Administration, Azithromycin, Infant and Child Mortality, Infant and Child health, Infant and Child growth, Infant and Child morbidity, Antimicrobial Resistance, Feasibility, Acceptability, Safety, Cost, Inflammation, Infection

Eligibility Criteria

29 Days - 364 Days (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

On a cluster (village) level:

  1. Location within Kayes, Kita, or Koulikoro region of Mali
  2. Considered accessible and safe by the local health authorities and research team
  3. Considered non-urban by the local health authorities and research team
  4. Permission from community leadership

On a household level (for trial enrollment):

  1. Location within a cluster that is included in the study
  2. Verbal consent from a head of household or an adult authorized by her / him

On a child level (for receiving study medication):

  1. Residence in a household enrolled in the trial
  2. Age between 29 and 364 days
  3. Verbal consent from at least one caregiver

Exclusion Criteria:

On child level (for not receiving study medication):

  1. Weight below 3.0 kg
  2. Known allergy to macrolides, as judged by a caregiver report of the infant experiencing an adverse reaction after oral ingestion of medication, which was deemed likely to be a macrolide by the interviewing data collector.

Sites / Locations

  • Center for Vaccine Development CVD-MaliRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Active Comparator

Active Comparator

Arm Label

Control

Azithromycin-biannually (Azi-biannual)

Azithromycin-quarterly

Arm Description

Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age: Single-dose of 0.5 ml / kg child weight Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of placebo mixture.

Azithromycin or placebo will be administered as a single dose in oral suspension form for children 1-11 months of age: Single-dose of 0.5 ml / kg child weight Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of study drug. Azithromycin will be given at quarterly visits between January and June, and Placebo mixture will be given at quarterly visits between July and December. Azithromycin dose will be 20 mg / kg.

Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age: Single-dose of 0.5 ml (20 mg) / kg child weight. Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of azithromycin.

Outcomes

Primary Outcome Measures

Mortality
Mortality rate (deaths per 1,000 years at risk) among children 1-11 months of age.

Secondary Outcome Measures

Morbidity
Morbidity (14-day period prevalence of fever with respiratory symptoms (ARI), fever without respiratory symptoms (malaria), and diarrhea) in children aged 4-14 months assessed in each participating cluster (village) from the secondary outcome sample.
Length-for-age Z-score
Length-for-age Z-score in 6-8 and 12-14 months old children from the secondary outcome sample. Length measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial. Length-for-age Z-score will be calculated using the WHO Child Growth Standards.
Weight-for age Z-score
Weight-for age Z-score in 6-8 and 12-14 months old children from the secondary outcome sample. Weight measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial. Weight-for-age Z-score will be calculated using the WHO Child Growth Standards.
Weight-for-length Z-score
Weight-for-length Z-score in 6-8 and 12-14 months old children from the secondary outcome sample. Length and weight measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial. Weight-for-length Z score will be calculated using the WHO Child Growth Standards.
Mid-upper arm circumference
Mid-upper arm circumference in 6-8 and 12-14 months old children from the secondary outcome sample. Measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial.
Percentage of moderate or severe stunting
Percentage of moderate or severe stunting (length-for-age Z-score < -2 / -3) in 6-8 and 12-14 months old children from the secondary outcome sample.
Percentage of moderate or severe wasting
Percentage of moderate or severe wasting (Weight-for-length Z-score < -2 / -3) in 6-8 and 12-14 months old children from the secondary outcome sample.
Prevalence of phenotypic and genotypic macrolide resistance
Prevalence of phenotypic and genotypic macrolide resistance among E. coli strains isolated from stool samples or S. pneumoniae strains isolated from nasopharyngeal swabs among among 4-14-month-old children, at one year after the MDA intervention has stopped (i.e., 36 months after MDA 1, the baseline). Genetic markers of azithromycin and other antibiotic resistance (resistome) of intestinal microbiota among 4-14-month-old children, at one year after the MDA intervention has stopped (i.e., 36 months after MDA 1, the baseline). (secondary outcome sample).
Prevalence of phenotypic and genotypic macrolide resistance
Prevalence of phenotypic and genotypic macrolide resistance among E. coli strains isolated from stool samples or S. pneumoniae strains isolated from nasopharyngeal swabs among 49-59-month-old children, at 24 months after village enrolment to the trial, i.e., after 8 rounds of MDA. (secondary outcome sample).
Prevalence of phenotypic and genotypic AMR resistance to other "ACCESS" group antibiotics
Prevalence of phenotypic and genotypic AMR against other antibiotics categorised by the World Health Organization (WHO) into "ACCESS" group, among azithromycin-resistant E. coli strains isolated from stool samples or azithromycin-resistant S. pneumoniae strains isolated from nasopharyngeal swabs (secondary outcome sample).
Blood C-reactive protein concentration
Biological samples taken from 4-11 months old infants to assess effect of azithromycin MDA on systemic inflammation (blood C-reactive protein concentration) (secondary outcome sample).
Blood malaria parasitemia and hemoglobin concentration
Biological samples taken from 4-11 months old infants to assess effect of azithromycin MDA on malaria prevalence and blood hemoglobin concentration (secondary outcome sample).
Fecal neopterin, myeloperoxidase, and alpha-1-antitrypsin concentrations
Biological samples taken from 4-11 months old infants to assess effect of azithromycin MDA on intestinal inflammation (secondary outcome sample).
Incidence of Adverse events
Incidence of adverse events within 14 days of study drug administration. Data collected from 4-11 months old infants at 9 months after enrollment (secondary outcome sample).
Incidence of Serious Adverse events
Incidence of serious adverse events (Death, life-threatening event, hospitalization, and other serious events as judged by a study physician) within 14 days of study drug administration, among 1-11 months old infants.
Mortality in children aged 12-59 month
Mortality rate (deaths per 1000 years at risk) among children who were 12-59 month old when the latest azithromycin MDA took place in their village of residence.
Percentage of guardians and health care workers reporting MDA acceptable
Data collected through interviews of guardians and health care workers to assess acceptability of MDA.
Percentage of the study population reached with MDA
Data collected on MDA distribution and through interviews of guardians and health care workers to assess equity of MDA.
Cost and Cost-effectiveness of the intervention
Data collected on MDA distribution to assess the economic aspects of MDA.The effectiveness will be determined by the trial outcome - both the primary outcome of mortality and the secondary outcomes of morbidity and possible AMR effects. The effectiveness will be expressed in different units such as deaths averted, or disability adjusted life years (DALYs).

Full Information

First Posted
May 22, 2020
Last Updated
October 4, 2022
Sponsor
Tampere University
Collaborators
Center for Vaccine Development CVD-Mali, Bamako, Mali, University College London Hospitals, Tro Da Ltd, UK, Duke-NUS Graduate Medical School, Bill and Melinda Gates Foundation (Funder), Pfizer Inc. (Provider of study drugs)
search

1. Study Identification

Unique Protocol Identification Number
NCT04424511
Brief Title
Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali
Acronym
LAKANA
Official Title
LAKANA , a Cluster-randomized, Double-blinded, Parallel Group, Controlled Trial, Testing the Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Rural Mali.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 15, 2020 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tampere University
Collaborators
Center for Vaccine Development CVD-Mali, Bamako, Mali, University College London Hospitals, Tro Da Ltd, UK, Duke-NUS Graduate Medical School, Bill and Melinda Gates Foundation (Funder), Pfizer Inc. (Provider of study drugs)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The LAKANA trial will assess the impact on mortality and other health outcomes of quarterly and biannual azithromycin mass drug administration (MDA) when delivered to 1-11-month (29-364 days) old infants in a high-mortality setting where malaria is holoendemic but there is also a functioning seasonal malaria chemoprevention (SMC) program in place. The long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality, and to determine the most effective treatment regimen. The main study hypotheses in terms of mortality effect are: i) Biannual azithromycin MDA to 1-11 month old infants reduces their mortality, ii) Quarterly azithromycin MDA to 1-11 month old infants reduces their mortality, iii) Quarterly azithromycin MDA has a bigger mortality effect than biannual MDA.
Detailed Description
Mass drug administration (MDA) of azithromycin has been shown to reduce under-5 mortality in some but not all sub-Saharan African settings. Because of the observed heterogeneity and possible effect modification by SMC or other co-interventions, further trials in new settings are needed in order to make evidence-based public health recommendations about the use of this treatment. The objectives of the LAKANA trial are: To evaluate the impact of two azithromycin MDA regimens on infant mortality and other health outcomes, when provided in a rural West-African high-mortality context with an ongoing seasonal malaria chemoprevention program. To evaluate the effect of alternative MDA frequencies on antimicrobial resistance (AMR) and host microbiota composition. To test hypotheses that azithromycin MDA eliminates malaria parasitaemia and reduces systemic and intestinal inflammation in asymptomatic children and to collect and store biological samples for assessing other possible mechanisms of azithromycin effect. To investigate the feasibility of alternative azithromycin MDA strategies, including economic analysis. The LAKANA trial will be conducted in 1150 villages from 7-10 health districts in the Kayes, Kita and Koulikoro regions of Mali. LAKANA is a cluster-randomized, placebo-controlled, double-blinded, parallel-group, three-arm clinical trial, with adaptive design. Participating villages will be randomly allocated to three different intervention groups in a ratio of 3 : 2 : 4 (control : azithromycin quarterly : azithromycin biannually). Within each participating village, consenting households will be visited quarterly (at 3-month intervals), nine times. At the first eight of these visits, 1-11-month-old eligible infants (age 29-364 days), for whom there is a consent for study drug provision, will be given a single dose of study drug (azithromycin mixture or respective placebo mixture). Mortality and serious adverse events (SAEs) data will be collected, and mortality-related questions answered using data from all the included 1150 villages. Mixed-effect Poisson regression model will be used to estimate the intervention effects on mortality, with random intercepts for the clusters. The investigators will explore effect modification by testing for interaction between the MDA intervention and the following variables: Infant age at the time of MDA (1-5 months vs 6-11 months) Infant weight-for-age at the time of MDA Infant sex Season of MDA dosing and time since the last SMC Cluster level coverage of SMC Cluster level baseline mortality (established at first census) Cluster and individual level coverage and number of administered azithromycin MDA doses District of residence Distance from the nearest health facility Household asset or income index Household WASH index The investigators will address the other study questions using a smaller separate secondary sample of 59 villages located around four selected health centers close to the city of Kita and a similar number of villages closer to Bamako, i.e. in Koulikoro or Kati (tertiary sample).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mortality
Keywords
Mass Drug Administration, Azithromycin, Infant and Child Mortality, Infant and Child health, Infant and Child growth, Infant and Child morbidity, Antimicrobial Resistance, Feasibility, Acceptability, Safety, Cost, Inflammation, Infection

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
LAKANA is a cluster-randomized, placebo-controlled, double-blinded, parallel-group, three-arm clinical trial, with adaptive design.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The investigators will utilize a matching placebo to mask study arm allocation. All children aged 1-11 months in all study communities will be offered biannual or quarterly azithromycin or placebo distribution in an identical fashion. Placebo will be identical to azithromycin in appearance, taste, odor, and packaging. The interventions will be coded only with a letter code.
Allocation
Randomized
Enrollment
100000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age: Single-dose of 0.5 ml / kg child weight Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of placebo mixture.
Arm Title
Azithromycin-biannually (Azi-biannual)
Arm Type
Active Comparator
Arm Description
Azithromycin or placebo will be administered as a single dose in oral suspension form for children 1-11 months of age: Single-dose of 0.5 ml / kg child weight Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of study drug. Azithromycin will be given at quarterly visits between January and June, and Placebo mixture will be given at quarterly visits between July and December. Azithromycin dose will be 20 mg / kg.
Arm Title
Azithromycin-quarterly
Arm Type
Active Comparator
Arm Description
Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age: Single-dose of 0.5 ml (20 mg) / kg child weight. Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of azithromycin.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
Intervention Type
Drug
Intervention Name(s)
Azithromycin
Intervention Description
Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
Primary Outcome Measure Information:
Title
Mortality
Description
Mortality rate (deaths per 1,000 years at risk) among children 1-11 months of age.
Time Frame
3-month time interval (total of 8 intervals per cluster)
Secondary Outcome Measure Information:
Title
Morbidity
Description
Morbidity (14-day period prevalence of fever with respiratory symptoms (ARI), fever without respiratory symptoms (malaria), and diarrhea) in children aged 4-14 months assessed in each participating cluster (village) from the secondary outcome sample.
Time Frame
3-month time interval (total of 8 intervals per cluster)
Title
Length-for-age Z-score
Description
Length-for-age Z-score in 6-8 and 12-14 months old children from the secondary outcome sample. Length measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial. Length-for-age Z-score will be calculated using the WHO Child Growth Standards.
Time Frame
3-month time interval (total of 3 intervals per cluster)
Title
Weight-for age Z-score
Description
Weight-for age Z-score in 6-8 and 12-14 months old children from the secondary outcome sample. Weight measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial. Weight-for-age Z-score will be calculated using the WHO Child Growth Standards.
Time Frame
3-month time interval (total of 3 intervals per cluster)
Title
Weight-for-length Z-score
Description
Weight-for-length Z-score in 6-8 and 12-14 months old children from the secondary outcome sample. Length and weight measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial. Weight-for-length Z score will be calculated using the WHO Child Growth Standards.
Time Frame
3-month time interval (total of 3 intervals per cluster)
Title
Mid-upper arm circumference
Description
Mid-upper arm circumference in 6-8 and 12-14 months old children from the secondary outcome sample. Measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial.
Time Frame
3-month time interval (total of 3 intervals per cluster)
Title
Percentage of moderate or severe stunting
Description
Percentage of moderate or severe stunting (length-for-age Z-score < -2 / -3) in 6-8 and 12-14 months old children from the secondary outcome sample.
Time Frame
3-month time interval (total of 3 intervals per cluster)
Title
Percentage of moderate or severe wasting
Description
Percentage of moderate or severe wasting (Weight-for-length Z-score < -2 / -3) in 6-8 and 12-14 months old children from the secondary outcome sample.
Time Frame
3-month time interval (total of 3 intervals per cluster)
Title
Prevalence of phenotypic and genotypic macrolide resistance
Description
Prevalence of phenotypic and genotypic macrolide resistance among E. coli strains isolated from stool samples or S. pneumoniae strains isolated from nasopharyngeal swabs among among 4-14-month-old children, at one year after the MDA intervention has stopped (i.e., 36 months after MDA 1, the baseline). Genetic markers of azithromycin and other antibiotic resistance (resistome) of intestinal microbiota among 4-14-month-old children, at one year after the MDA intervention has stopped (i.e., 36 months after MDA 1, the baseline). (secondary outcome sample).
Time Frame
12-month time interval (total of 3 intervals per cluster)
Title
Prevalence of phenotypic and genotypic macrolide resistance
Description
Prevalence of phenotypic and genotypic macrolide resistance among E. coli strains isolated from stool samples or S. pneumoniae strains isolated from nasopharyngeal swabs among 49-59-month-old children, at 24 months after village enrolment to the trial, i.e., after 8 rounds of MDA. (secondary outcome sample).
Time Frame
12-month time interval (total of 3 intervals per cluster)
Title
Prevalence of phenotypic and genotypic AMR resistance to other "ACCESS" group antibiotics
Description
Prevalence of phenotypic and genotypic AMR against other antibiotics categorised by the World Health Organization (WHO) into "ACCESS" group, among azithromycin-resistant E. coli strains isolated from stool samples or azithromycin-resistant S. pneumoniae strains isolated from nasopharyngeal swabs (secondary outcome sample).
Time Frame
12-month time interval (total of 3 intervals per cluster)
Title
Blood C-reactive protein concentration
Description
Biological samples taken from 4-11 months old infants to assess effect of azithromycin MDA on systemic inflammation (blood C-reactive protein concentration) (secondary outcome sample).
Time Frame
Biological samples taken before and 14 days after the fourth MDA round, 9 months after enrollment.
Title
Blood malaria parasitemia and hemoglobin concentration
Description
Biological samples taken from 4-11 months old infants to assess effect of azithromycin MDA on malaria prevalence and blood hemoglobin concentration (secondary outcome sample).
Time Frame
Biological samples taken before and 14 days after the fourth MDA round, 9 months after enrollment.
Title
Fecal neopterin, myeloperoxidase, and alpha-1-antitrypsin concentrations
Description
Biological samples taken from 4-11 months old infants to assess effect of azithromycin MDA on intestinal inflammation (secondary outcome sample).
Time Frame
Biological samples taken before and 14 days after the fourth MDA round, 9 months after enrollment.
Title
Incidence of Adverse events
Description
Incidence of adverse events within 14 days of study drug administration. Data collected from 4-11 months old infants at 9 months after enrollment (secondary outcome sample).
Time Frame
3-month time interval
Title
Incidence of Serious Adverse events
Description
Incidence of serious adverse events (Death, life-threatening event, hospitalization, and other serious events as judged by a study physician) within 14 days of study drug administration, among 1-11 months old infants.
Time Frame
within 14 days after MDA round.
Title
Mortality in children aged 12-59 month
Description
Mortality rate (deaths per 1000 years at risk) among children who were 12-59 month old when the latest azithromycin MDA took place in their village of residence.
Time Frame
3-month time interval (total of 8 intervals per cluster)
Title
Percentage of guardians and health care workers reporting MDA acceptable
Description
Data collected through interviews of guardians and health care workers to assess acceptability of MDA.
Time Frame
24 months after enrollment
Title
Percentage of the study population reached with MDA
Description
Data collected on MDA distribution and through interviews of guardians and health care workers to assess equity of MDA.
Time Frame
24 months after enrollment
Title
Cost and Cost-effectiveness of the intervention
Description
Data collected on MDA distribution to assess the economic aspects of MDA.The effectiveness will be determined by the trial outcome - both the primary outcome of mortality and the secondary outcomes of morbidity and possible AMR effects. The effectiveness will be expressed in different units such as deaths averted, or disability adjusted life years (DALYs).
Time Frame
24 months after enrollment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
29 Days
Maximum Age & Unit of Time
364 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: On a cluster (village) level: Location within Kayes, Kita, or Koulikoro region of Mali Considered accessible and safe by the local health authorities and research team Considered non-urban by the local health authorities and research team Permission from community leadership On a household level (for trial enrollment): Location within a cluster that is included in the study Verbal consent from a head of household or an adult authorized by her / him On a child level (for receiving study medication): Residence in a household enrolled in the trial Age between 29 and 364 days Verbal consent from at least one caregiver Exclusion Criteria: On child level (for not receiving study medication): Weight below 3.0 kg Known allergy to macrolides, as judged by a caregiver report of the infant experiencing an adverse reaction after oral ingestion of medication, which was deemed likely to be a macrolide by the interviewing data collector.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Per Ashorn, MD, PhD
Phone
407280345
Ext
+358
Email
per.ashorn@tuni.fi
First Name & Middle Initial & Last Name or Official Title & Degree
Ulla Ashorn, PhD
Phone
407080354
Ext
+358
Email
ulla.ashorn@tuni.fi
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Per Ashorn, MD, PhD
Organizational Affiliation
Center for Child Health Research, Tampere University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ulla Ashorn, PhD
Organizational Affiliation
Center for Child Health Research, Tampere University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Samba Sow, MD, MSc
Organizational Affiliation
Center for Vaccine Development CVD-Mali
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nigel Klein, MBBS, PhD
Organizational Affiliation
University College London Hospitals
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Camilla Ducker, MBBS, MSc
Organizational Affiliation
Tro Da Ltd, UK
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yin Bun Cheung, PhD
Organizational Affiliation
Centre for Quantitative Medicine, Duke-NUS Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Vaccine Development CVD-Mali
City
Bamako
ZIP/Postal Code
BP 251
Country
Mali
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samba Sow, MD, MSc
Phone
76348947
Ext
+223
Email
ssow@som.umaryland.edu
First Name & Middle Initial & Last Name & Degree
Camilla Ducker, MBBS, MSc
Email
camilla@troda.org
First Name & Middle Initial & Last Name & Degree
Samba Sow, MD, MSc

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data collected during the trial, after deidentification. (The details are to be determined).
IPD Sharing Time Frame
Starting 6 months after publication
IPD Sharing Access Criteria
(The details are to be determined)

Learn more about this trial

Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali

We'll reach out to this number within 24 hrs